How should Brugada syndrome be managed, including trigger avoidance, pharmacologic therapy, and device implantation?

Management of Brugada Syndrome

All patients with Brugada syndrome must immediately avoid specific triggers and receive risk-stratified treatment, with ICD implantation being the definitive therapy for those with cardiac arrest, documented sustained VT, or spontaneous Type 1 ECG with syncope. 1, 2

Immediate Universal Measures for ALL Patients

Regardless of symptom status, every patient diagnosed with Brugada syndrome requires these lifestyle modifications 1:

• Avoid all drugs listed on www.brugadadrugs.org (includes sodium channel blockers, certain psychotropic medications, anesthetic agents, cocaine) 3
• Avoid excessive alcohol intake and large meals (both unmask Type 1 ECG and trigger VF)
• Aggressively treat any fever with antipyretics immediately (fever is a major VF trigger) 3

Risk Stratification and ICD Decision Algorithm

Class I Indications (ICD Mandatory):

Implant an ICD in patients with: 1, 2

• Survivors of cardiac arrest, OR
• Documented spontaneous sustained VT, OR
• Spontaneous Type 1 ECG pattern AND history of syncope presumed due to ventricular arrhythmia

These patients have the highest mortality risk (13.5% per year for cardiac arrest survivors, 3.2% per year with syncope) 1. The ICD is the only proven therapy to prevent sudden cardiac death 3.

Class IIa Indication (ICD Should Be Considered):

Consider ICD for: 4, 1

• Spontaneous Type 1 ECG pattern with syncope (even if not definitively arrhythmic)

Class IIb Indication (ICD May Be Considered):

ICD may be considered for: 1, 2

• Inducible VF during electrophysiology study with 2-3 extrastimuli at two sites

Critical caveat: The prognostic value of EP studies remains controversial—most studies show neither positive nor negative predictive value for cardiac events 1. Use EP studies cautiously for risk stratification in asymptomatic patients 2.

Observation Only (No ICD):

Asymptomatic patients with: 2

• Only drug-induced Type 1 pattern (not spontaneous)
• No history of syncope or cardiac arrest
• Annual event rate: 1% per year 1

Pharmacologic Therapy

For Electrical Storms or Recurrent ICD Shocks:

Quinidine or isoproterenol is recommended 1, 2. These agents rebalance ion channel currents by either inhibiting transient outward current (Ito) or boosting calcium channel current 5, 6.

For ICD-Ineligible or ICD-Refusing Patients:

Quinidine should be considered as an alternative 1. One series showed no deaths over 9 years of quinidine therapy, though 38% experienced adverse effects 3.

For Supraventricular Arrhythmias:

Quinidine is reasonable for concurrent supraventricular arrhythmia management 1.

Catheter Ablation

Ablation may be considered for: 1, 2

• Electrical storms despite medical therapy
• Repeated appropriate ICD shocks

Ablation targets abnormal epicardial late activation areas in the right ventricular outflow tract. Small series show >75% elimination of spontaneous Type 1 pattern and marked reduction in VT/VF recurrence 3. However, experience remains limited—maintain ICD even after successful ablation 3.

Genetic Testing

Genetic counseling and testing may be useful to facilitate cascade screening of family members 2, 3. However, only 20-30% of phenotype-positive patients have identifiable mutations (mostly SCN5A), and genetic results do not currently influence prognosis or treatment decisions 1, 3.

Common Pitfalls to Avoid

1. Do not rely solely on EP studies for risk stratification in asymptomatic patients—the evidence is conflicting 1, 3
2. Do not implant ICDs just to enable athletic participation—treatment decisions must be based on disease severity, not athlete status 7
3. Do not miss drug-induced Brugada patterns—use sodium channel blocker challenge when suspicion exists without spontaneous Type 1 pattern 2, 3
4. Do not overlook high precordial lead placement (2nd-3rd intercostal spaces) for ECG recording—this improves Type 1 pattern detection 3
5. Beware of inappropriate ICD shocks—they occur in 18.7% of patients despite careful programming 8. Device-related complications affect 15.9% of patients 8

Special Consideration: Atrial Fibrillation

AF occurs in 6-39% of BrS patients, particularly those with SCN5A variants 9. Critical warning: Unrecognized BrS in patients presenting with AF may lead to inappropriate sodium channel blocker administration, potentially triggering fatal ventricular arrhythmias 9. Consider pulmonary vein isolation rather than antiarrhythmic drugs for AF management in these patients 9.